Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126437901 | 12643790 | 1 | I | 20160608 | 20160811 | 20160811 | PER | US-GLENMARK PHARMACEUTICALS INC, USA.-2016GMK023293 | GLENMARK | FOX L.M., BIARY R., HOFFMAN R.S., HOWLAND M.A., NELSON L.S., SMITH S.W.. CO-ADMINISTRATION OF METHADONE AND ONDANSETRON ASSOCIATED WITH TORSADES DE POINTES. CLINICAL TOXICOLOGY.. 2016;54(4):427 | 0.00 | Y | 0.00000 | 20160811 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126437901 | 12643790 | 1 | PS | Ondansetron | ONDANSETRON | 1 | Intravenous (not otherwise specified) | 4 MG, UNK, AT NIGHT | U | 0 | 4 | MG | |||||||
| 126437901 | 12643790 | 2 | SS | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 80 MG, UNK, ONE HOUR AFTER ARRIVAL | U | 0 | 80 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126437901 | 12643790 | 1 | Product used for unknown indication |
| 126437901 | 12643790 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126437901 | 12643790 | OT |
| 126437901 | 12643790 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126437901 | 12643790 | Torsade de pointes |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |